THE HORMONAL PROFILE IN WOMEN AT HIGH RISK FOR OVARIAN HYPERSTIMULATION SYNDROME AFTER REPLACEMENT OF AN OVULATION TRIGGER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the time course of changes in the concentrations of sex hormones in the serum and follicular fluid of patients at high risk for ovarian hyperstimulation syndrome (OHSS) when replacing an ovulation trigger and during different variants of luteal phase support. Subjects and methods. The investigation enrolled 134 patients aged 20 to 39 years at high risk for OHSS. The patients were divided into three groups according to the injected ovulation trigger: 1) gonadotropin-releasing hormone (GnRH) agonist (GnRH-α) 0.2 mg (n = 48); 2) GnRH-α 0.2 mg in combination with human chorionic gonadotropin (hCG) 1500 IU (n = 45); 3) hCG 10,000 IU (n = 41). Micronized progesterone 600 mg/day and estradiol valerate 4 mg/day were used for luteal phase support in Groups 1 and 2. In Group 1, hCG was additionally injected in a dose of 1500 IU for luteal phase support on the day of transvaginal puncture (TVP). In Group 3, micronized progesterone was administered in a dose of 600 mg/day for luteal phase support. To estimate the concentrations of luteinizing hormone (LH), estradiol, and progesterone, peripheral blood was sampled on the days of ovulation triggering and TVP and on days 3 and 5 after TVP. The follicular fluid hormonal profile was determined in 66 patients: 23 women in Group 1, 23 women in Group 2, and 20 women in Group 3. Results. Analysis of the hormonal profile of the examined groups revealed that LH concentrations were statistically higher in the GnRH-α and GnRH-α + hCG groups than those in the hCG group. Estradiol on day 3 following TVP was statistically significantly higher in the GnRH-α group than in the hCG group whereas that on day 5 statistically significantly reduced in the GnRH-α + hCG group than in Groups 1 and 3. There was a statistically significant decrease in progesterone concentrations on day 5 after TVP in the GnRH-α + hCG group than in the Groups 1 and 3. In the GnRH-α group, progesterone concentrations on days 3 and 5 following TVP were comparable with those in the hCG group. The incidence of mild OHSS was 16.7% in Group 1, 27.3% in Group 2, and 36.6% in Group 3. In the GnRH-α group, all cases belonged to late OHSS that occurred during conception. No matter what ovulation trigger was used, the embryological parameters were identical in all the examined groups. There were no statistically significant differences in the rate of conception after embryo transfer and in that of pregnancy termination in all the groups. Conclusion. Modified support of the luteal phase effectively correlates its failure after replacement of an ovulation trigger, which enables effective prevention of OHSS, without having any impact on the rate of conception.

Full Text

Restricted Access

About the authors

B. A MARTAZANOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: bellamart88@mail.ru
graduate student Moscow 117997, Ac. Oparina str. 4, Russia

N. G MISHIEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: nondoc555@mail.ru
MD, Senior researcher of 1st gynecology department Moscow 117997, Ac. Oparina str. 4, Russia

I. A VEDIKHINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: i_vedikhina@oparina4.ru
Biologist of the Scientific Diagnostical Laboratory Moscow 117997, Ac. Oparina str. 4, Russia

A. A AKSENENKO

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_axenenko@oparina4.ru
doctor of 1st gynecology department Moscow 117997, Ac. Oparina str. 4, Russia

S. M EAPEN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: dr.snehaeapen@gmail.com
graduate student Moscow 117997, Ac. Oparina str. 4, Russia

M. Kh IBRAGIMOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: habibi_m@mail.ru
PhD, doctor of 1st gynecology department Moscow 117997, Ac. Oparina str. 4, Russia

T. Yu IVANETS

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: t_ivanets@oparina4.ru
Head of the Scientific Diagnostical Laboratory Moscow 117997, Ac. Oparina str. 4, Russia

A. N ABUBAKIROV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: nondoc555@yahoo.com
PhD, Head of 1-st gynecology department Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Kessler M.J., Reddy M.S., Shah R.H., Bahl O.P. Structures of N-glycosidiccarbohydrate units of human chorionic gonadotropin. J. Biol. Chem. 1979; 254(16): 7901-8.
  2. Damewood M.D., Shen W., Zacur H.A., Schlaff W.D., Rock J.A., Wallach E.E. Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril. 1989; 52(3): 398-400.
  3. Sharpless J.L., Supko J.G., Martin K.A., Hall J.E. Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women. J. Clin. Endocrinol. Metab. 1999; 84(2): 688-94.
  4. Yen S.S., Llerena O., Little B., Pearson O.H. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J. Clin. Endocrinol. Metab. 1968; 28(12): 1763-7.
  5. Fauser B.C., de Jong D., Olivennes F., Wramsby H., Tay C., Itskovitz-Eldor J., Van Hooren H.G. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab. 2002; 87(2):709-15.
  6. Damewood M.D., Shen W., Zacur H.A., Schlaff W.D., Rock J.A., Wallach E.E. Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril. 1989; 52(3): 398-400.
  7. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil. Steril. 2004; 81(1): 1-5.
  8. Hoff J.D., Quigley M.E., Yen S.S. Hormonal dynamics at midcycle: a revaluation. J. Clin. Endocrinol. Metab. 1983; 57(4): 792-6.
  9. ChandrasekherY.A.,Hutchison J.S., Zelinski-Wooten M.B., Hess D.L., Wolf D.P., Stouffer R.L. Initiation of periovulatory events in primate follicles using recombinant and native human luteinizing hormone to mimic the midcycle gonadotropin surge. J. Clin. Endocrinol. Metab. 1994; 79(1): 298-306.
  10. Itskovitz J., Boldes R., Levron J., Erlik Y., Kahana L., Brandes J.M. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil. Steril. 1991; 56(2): 213-20.
  11. Andersen C.Y., Andersen K.V. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod. Biomed. Online. 2014; 28(5): 552-9.
  12. Itskovitz J., Boldes R., Barlev A., Erlik Y., Kahana L., Brandes J.M. The induction of LH surge and oocyte maturation by GnRH analogue (buserelin) in women undergoing ovarian stimulation for in vitro fertilisation. Gynecol. Endocrinol. 1988; 2(Suppl. 2): 165.
  13. Youssef M.A., Van der Veen F., Al-Inany H.G., Griesinger G., Mochtar M.H., Aboulfoutouh I. et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggeringin antagonist assisted productive technology cycles. Cochrane Database Syst. Rev. 2011; (1): CD008046.
  14. Acevedo B., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril. 2006; 86(6): 1682-7.
  15. Humaidan P., Bredkjaer H.E., Bungum L., Bungum M., Grøndahl M.L., Westergaard L., Andersen C.Y. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum. Reprod. 2005; 20(5): 1213-20.
  16. Andersen C.Y., Humaidan P., Ejdrup H.B., Bungum L., Grøndahl M.L., Westergaard L.G. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum. Reprod. 2006; 21(8): 2126-30.
  17. Leth-Moller K., Hammer Jagd S., Humaidan P. The luteal phase after GnRHa trigger-understanding an enigma. Int. J. Fertil. Steril. 2014; 8(3): 227-34.
  18. Lee T.H., Liu C.H., Huang C.C., Wu Y.L., Shih Y.T., Ho H.N., Yang Y.S., Lee M.S. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod. 2008; 23(1): 160-7.
  19. Kwee J., Schats R., McDonnell J., Themmen A., de Jong F., Lambalk C. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil. Steril. 2008; 90(3): 737-43.
  20. Golan A., Ron-El R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. 1989; 44(6): 430-40.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies